BiotechTube
Iaso Therapeutics

Iaso Therapeutics

Cambridge, United States· Est.
iasotherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $26.8M

Overview

Iaso Therapeutics is a private, preclinical-stage biotech founded in 2020 and headquartered in Cambridge, Massachusetts, with operations also noted in East Lansing, Michigan. The company's core asset is a disruptive synthetic vaccine platform based on a mutant Qβ VLP carrier, designed for rapid design-to-clinic timelines and superior immunogenicity compared to traditional carrier proteins. Iaso is pre-revenue and is advancing its platform technology, with an initial focus on infectious disease vaccines, supported by entities like the National Science Foundation.

Infectious Diseases

Technology Platform

Mutant Qβ (mQβ) virus-like particle (VLP) platform for synthetic antigen conjugation, designed for rapid development, high immunogenicity, low anti-carrier response, and potential room-temperature stability.

Funding History

2
Total raised:$26.8M
Series A$22M
Seed$4.8M

Opportunities

The escalating global antimicrobial resistance (AMR) crisis creates a urgent need for preventive vaccines, representing a large and growing market.
The platform's focus on rapid development, broad-spectrum coverage, and room-temperature stability aligns with key unmet needs in pandemic preparedness and global health accessibility.

Risk Factors

The company faces high technical risk as its novel platform is unproven in clinical trials.
As a pre-revenue, private company, it is dependent on securing sufficient funding to advance expensive development work.
It also operates in a highly competitive landscape against established vaccine technologies and large pharma players.

Competitive Landscape

Iaso competes in the novel vaccine platform space against companies developing mRNA, other VLP, and nanoparticle technologies from firms like Moderna, BioNTech, CureVac, and others. Its specific focus on conjugate vaccine improvement pits it against established carriers (CRM197, TT) used in many commercial bacterial vaccines.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →